Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Phase 2 Unknown 66 enrolled Qilu Pharmaceutical Co., Ltd.

NaSequentialOpen-labelTreatment

Summary

This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.

Timeline

Start: 2023-04-24
Primary completion: 2023-10
Completion: 2024-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QLF31907	Unknown	—	Intravenous

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Summary

Timeline

Drugs

Indications